Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dermacyd PH_DETINLYN Tangerine Mix · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dermacyd PH\_DETINLYN Tangerine Mix (Lactic Acid) |
| Name | Type | Description |
|---|---|---|
| Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) | DRUG | - |
Inclusion criteria: * Integral skin test in the region; * Use of cosmetic product of the same category; * Willingness in following the study procedures and to be present in the clinic at the days and scheduled time; Exclusion criteria: * Lactation or gestational risk or gestation; * Use of Anti-i...
Dermacyd PH_DETINLYN Tangerine Mix is used for hygiene purposes. It is a small molecule product being developed by Sanofi. The product is intended for use in females aged 10 years and older, as indicated by the clinical trial that enrolled healthy female volunteers in Brazil.
Sanofi (ticker: SNY) is the developer of Dermacyd PH_DETINLYN Tangerine Mix. The company is conducting clinical development of this hygiene product, which is currently in Phase 3 trials.
Dermacyd PH_DETINLYN Tangerine Mix is in Phase 3 clinical development. It is an investigational product and has not been approved by regulatory authorities. The Phase 3 trial has been completed, with a total of 30 participants enrolled.
Dermacyd PH_DETINLYN Tangerine Mix has one completed clinical trial, identified as NCT00785642. The trial, titled 'Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Safety,' was a Phase 3 study conducted in Brazil with 30 female participants aged 10 years and older.
Dermacyd PH_DETINLYN Tangerine Mix contains lactic acid as an active ingredient, as indicated by the clinical trial title. The product is a hygiene product being developed by Sanofi, and the completed Phase 3 trial assessed its safety in healthy female volunteers.